
GUTS Stock Forecast & Price Target
GUTS Analyst Ratings
Bulls say
Fractyl Health is a promising investment choice based on their innovative approach to treating metabolic diseases, as evidenced by their authorization for a clinical trial of RJVA-001 and positive results for their weight loss procedure, Revita. The company's plans to expedite FDA approval and explore new classifications for their treatments demonstrate their strong potential for success, but investors should consider the inherent risks of the medical and biotech industry when considering an investment in Fractyl Health.
Bears say
Fractyl Health is facing potential challenges and risks in obtaining regulatory approval and reimbursement for their novel metabolic disease treatments, which could delay their ability to bring products to market and generate revenue. While initial data for their lead product candidate, Revita, and the Rejuva candidate show promise, they are based on small sample sizes and relatively short follow-up periods. Furthermore, the company's timing guidance for pivotal data has been narrowed, putting more pressure on them to deliver positive results in the near future. These factors, combined with a lack of other significant financial data, contribute to a negative outlook on Fractyl Health's stock.
This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GUTS Analyst Forecast & Price Prediction
Start investing in GUTS
Order type
Buy in
Order amount
Est. shares
0 shares